Universal Biosensors Inc

Chart & Performance

D1W1MN

P/E

—

P/S

4.72

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

3.69%

Rev. gr., 5y

-37.48%

Revenues

+46.58%

Net income

-7m

L-74.90%

CFO

-15m

L-0.57%

Earnings

Jan 29, 2025

Profile

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips; and distributes Siemens' Xprecia Stride Coagulation Analyzer, a test used to monitor the effect of the anticoagulant therapy warfarin. The company also manufactures and distributes Sentia SO2 test strips; and distributes Sentia Analyzer for the use in measurement of free SO2 levels in post-fermentation wine. In addition, it offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a biosensor strip and a meter to be used for the detection and monitoring of diabetes in animals. Universal Biosensors, Inc. was incorporated in 2001 and is headquartered in Rowville, Australia.

URL

http://www.universalbiosensors.com/

IPO date

Dec 13, 2006

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	6,633 46.58%	4,525 -21.68%
Cost of revenue	7,322	14,678
Unusual Expense (Income)
NOPBT	(690)	(10,153)
NOPBT Margin
Operating Taxes	(3,496)	(3,051)
Tax Rate
NOPAT	2,806	(7,102)
Net income	(6,742) -74.90%	(26,855) 160.68%
Dividends
Dividend yield
Proceeds from repurchase of equity	(30)	24,973
BB yield	0.07%	-55.85%
Debt
Debt current	1,746	830
Long-term debt	7,286	8,762
Deferred revenue		(47)
Other long-term liabilities	1,290	2,969
Net debt	(1,529)	(16,706)
Cash flow
Cash from operating activities	(14,619)	(14,702)
CAPEX	(1,473)	(1,565)
Cash from investing activities	(1,473)	(1,565)
Cash from financing activities	(83)	25,011
FCF	(3,249)	(10,016)
Balance
Cash	10,240	25,978
Long term investments	320	320
Excess cash	10,229	26,071
Stockholders' equity	(99,731)	(92,949)
Invested Capital	125,501	126,792
ROIC	2.22%
ROCE
EV
Common stock shares outstanding	212,369	198,725
Price	0.20 -11.11%	0.23 -77.27%
Market cap	42,474 -5.01%	44,713 -74.59%
EV	40,945	28,007
EBITDA	280	(7,367)
EV/EBITDA	146.14
Interest	177	18
Interest/NOPBT